BioSpace News Archive

Bristol Myers Squibb announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis were free of six-month confirmed disability progression.

InDex Pharmaceuticals Holding AB announced that 30% of patients have completed the final visit in Induction Study 1 of the phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis.

Orexo AB, reports top line results after having completed a study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder and reduction in use of illicit opioids.

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the wellbeing of psoriasis patients and their families through treatments and cutting-edge research.

AM-Pharma B.V. announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia patients.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced collaboration with 3M Health Care.

Pathnostics, a leading diagnostic solutions company, announced the publication of clinical study results showing that its advanced urinary tract infection test profoundly impacts patient care.

PolyPid Ltd. announced that it has received a written notice from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities, including the Company’s ordinary shares, to maintain a minimum bid price of $1.00 per share.

Femasys Inc. announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The Nasdaq Capital Market.